A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro

Dovitinib (TKI258) is a small molecule multi-kinase inhibitor currently in clinical phase I/II/III development for the treatment of various types of cancers. This drug has a safe and effective pharmacokinetic/pharmacodynamic profile. Although dovitinib can bind several kinases at nanomolar concentra...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yura, Bae, Kyoung Jun, Chon, Hae Jung, Kim, Seong Hwan, Kim, Soon Ae, Kim, Jiyeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Molecular and Cellular Biology 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870186/
https://www.ncbi.nlm.nih.gov/pubmed/27025387
http://dx.doi.org/10.14348/molcells.2016.2300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870186/
https://www.ncbi.nlm.nih.gov/pubmed/27025387
http://dx.doi.org/10.14348/molcells.2016.2300

Ejemplares similares